ES2589139T3 - Esteroides de androstano y pregnano con potentes propiedades de modulación alostérica del complejo receptor GABA/ionóforo cloruro - Google Patents

Esteroides de androstano y pregnano con potentes propiedades de modulación alostérica del complejo receptor GABA/ionóforo cloruro Download PDF

Info

Publication number
ES2589139T3
ES2589139T3 ES08771137.0T ES08771137T ES2589139T3 ES 2589139 T3 ES2589139 T3 ES 2589139T3 ES 08771137 T ES08771137 T ES 08771137T ES 2589139 T3 ES2589139 T3 ES 2589139T3
Authority
ES
Spain
Prior art keywords
aryl
alkyl
substituted
optionally substituted
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08771137.0T
Other languages
English (en)
Spanish (es)
Inventor
Scott P. Runyon
Michael Rogawski
John Kepler
Hernan Navarro
Rafal Kaminski
Matthew Orr
Edgar Cook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RTI International Inc
US Department of Health and Human Services
Original Assignee
RTI International Inc
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RTI International Inc, US Department of Health and Human Services filed Critical RTI International Inc
Application granted granted Critical
Publication of ES2589139T3 publication Critical patent/ES2589139T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
ES08771137.0T 2007-06-15 2008-06-16 Esteroides de androstano y pregnano con potentes propiedades de modulación alostérica del complejo receptor GABA/ionóforo cloruro Active ES2589139T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94425707P 2007-06-15 2007-06-15
US944257P 2007-06-15
PCT/US2008/067059 WO2008157460A1 (en) 2007-06-15 2008-06-16 Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties

Publications (1)

Publication Number Publication Date
ES2589139T3 true ES2589139T3 (es) 2016-11-10

Family

ID=40156649

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08771137.0T Active ES2589139T3 (es) 2007-06-15 2008-06-16 Esteroides de androstano y pregnano con potentes propiedades de modulación alostérica del complejo receptor GABA/ionóforo cloruro

Country Status (7)

Country Link
US (3) US8575375B2 (enExample)
EP (1) EP2155204B1 (enExample)
JP (3) JP5663303B2 (enExample)
AU (1) AU2008265898B2 (enExample)
CA (1) CA2698172C (enExample)
ES (1) ES2589139T3 (enExample)
WO (1) WO2008157460A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2698172C (en) * 2007-06-15 2014-02-18 Cook, Kevin M. Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
US20110086828A1 (en) * 2009-10-07 2011-04-14 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Treatment of alcohol abuse and alcoholism using modulators of neurosteroid binding sites on gabaa receptors
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
CA3152410A1 (en) 2011-10-14 2013-04-18 Sage Therapeutics, Inc. 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders
SMT202000008T1 (it) 2012-01-23 2020-03-13 Sage Therapeutics Inc Formulazione di steroide neuroattivo comprendente un complesso di allopregnanolone e solfobutil eter beta-ciclodestrina
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
PL2887944T3 (pl) 2012-08-21 2022-02-21 Sage Therapeutics, Inc. Allopregnanolon do leczenia lekoopornego stanu padaczkowego
ES2973320T3 (es) 2012-11-30 2024-06-19 Univ California Alopregnanolona para tratar, reducir o mitigar los síntomas de la depresión posparto
TR201808616T4 (tr) 2012-12-18 2018-07-23 Sage Therapeutics Inc Nöroaktif 19-alkoksi-17-ikameli steroidler, bunların ön ilaçları ve bunları kullanan tedavi yöntemleri.
CN113527400B (zh) 2013-04-17 2024-06-28 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
RU2019126333A (ru) * 2013-04-17 2019-10-08 Сейдж Терапьютикс, Инк. 19-нор нейроактивные стероиды и способы их применения
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
WO2015010054A2 (en) 2013-07-19 2015-01-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
AU2014308621C1 (en) 2013-08-23 2022-01-06 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3188734A4 (en) 2014-09-02 2018-01-10 The Texas A&M University System Method of treating organophosphate intoxication
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
SMT202000414T1 (it) 2014-10-16 2020-09-10 Sage Therapeutics Inc Composizioni e metodi per trattare disturbi del snc
MX2021004492A (es) 2014-10-16 2022-12-05 Sage Therapeutics Inc Composiciones para el tratamiento de trastornos del snc.
ME03749B (me) 2014-11-27 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCIZA LEČENJE POREMEĆAJA CNS-a
DK3250210T3 (da) 2015-01-26 2021-03-08 Sage Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
JP6875996B2 (ja) 2015-02-20 2021-05-26 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
AR105044A1 (es) 2015-06-18 2017-08-30 Sage Therapeutics Inc Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente
RU2766155C2 (ru) 2016-03-08 2022-02-08 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, их композиции и применения
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
CA3030420C (en) 2016-07-11 2025-11-18 Sage Therapeutics, Inc. C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
EP3507093A4 (en) * 2016-08-30 2020-04-08 Rize Inc. Method of fabricating a three-dimensional object with removable support structure
CA3075038A1 (en) * 2017-09-07 2019-03-14 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
JP7648538B2 (ja) 2019-04-27 2025-03-18 ヘルス リサーチ インコーポレイテッド 前立腺癌の治療のためのクマリン修飾アンドロゲン
CN114206900A (zh) 2019-05-31 2022-03-18 萨奇治疗股份有限公司 神经活性类固醇及其组合物
CN111057120B (zh) * 2019-12-27 2021-04-27 苏州翔实医药发展有限公司 一种依托孕烯衍生物a及其制备方法和用途
JP2023527288A (ja) * 2020-05-18 2023-06-28 ヴィスタゲン セラピューティクス、インコーポレイテッド 適応障害の治療
WO2023060067A1 (en) 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Amorphous solid dispersion ganaxolone formulation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2753361A (en) * 1955-02-01 1956-07-03 Searle & Co 17-thio-5-androstene-3-ols
US2763669A (en) * 1955-03-01 1956-09-18 Searle & Co delta-17-thio-androsten-3-ones
US2847427A (en) * 1957-09-09 1958-08-12 Searle & Co Delta or 5,16 androstadien-17-alkylsulfones and sulfoxides
US3001986A (en) * 1960-07-14 1961-09-26 Searle & Co 3-oxygenated 17 - amino - 17 - carboxyethylandrostane lactams and delta4 compounds corresponding
US3094522A (en) * 1961-07-25 1963-06-18 Merck & Co Inc Alkanoylthio and pyrazolo androstane derivatives
US3094521A (en) 1961-07-25 1963-06-18 Merck & Co Inc Alkanoylthio and pyrazolo androstane derivatives
US4891367A (en) * 1987-04-22 1990-01-02 Merrell Dow Pharmaceuticals Inc. 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
DK0752860T3 (da) 1994-02-14 2000-11-13 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
CN1187053C (zh) * 1997-10-06 2005-02-02 利兰·斯坦福青年大学托管委员会 糖皮质素受体拮抗剂用于制造治疗精神病药物的用途
US5962444A (en) * 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
CA2698172C (en) 2007-06-15 2014-02-18 Cook, Kevin M. Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties

Also Published As

Publication number Publication date
US20170051008A1 (en) 2017-02-23
EP2155204B1 (en) 2016-08-17
US20110092473A1 (en) 2011-04-21
CA2698172C (en) 2014-02-18
JP5990557B2 (ja) 2016-09-14
US10087211B2 (en) 2018-10-02
JP5663303B2 (ja) 2015-02-04
JP2015003925A (ja) 2015-01-08
AU2008265898B2 (en) 2013-11-28
WO2008157460A8 (en) 2010-03-25
US20140094619A1 (en) 2014-04-03
JP2015007128A (ja) 2015-01-15
JP5828159B2 (ja) 2015-12-02
CA2698172A1 (en) 2008-12-24
AU2008265898A1 (en) 2008-12-24
WO2008157460A1 (en) 2008-12-24
EP2155204A4 (en) 2011-05-25
US9518080B2 (en) 2016-12-13
JP2010530004A (ja) 2010-09-02
EP2155204A1 (en) 2010-02-24
US8575375B2 (en) 2013-11-05

Similar Documents

Publication Publication Date Title
CA2698172C (en) Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
ES2927007T3 (es) Esteroides neuroactivos, composiciones y usos de los mismos
JP2024522990A (ja) 抗ウイルス薬としてのプロテアーゼ阻害剤
PT99483A (pt) Processo para a preparacao de antagonistas de oxitocina de piperidinilcanfro- -sulfonilo
ES2884071T3 (es) 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
JP7810643B2 (ja) ベンゾチオフェン誘導体レギュレーター、その調製法及び使用
ES2270596T3 (es) 17-beta-amino e hidroxilamino-11 beta-arilesteroides y sus derivados que tienen propiedades hormonales agonistas o antagonistas.
CA2333668C (en) 17.beta.-nitro-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties
JP2025524970A (ja) 抗体－薬物コンジュゲートおよびその使用
JP5731397B2 (ja) ３，５−セコ−４−ノル−コレスタンの新規オキシム誘導体、それを含む医薬組成物、及びその調製方法
ES2228584T3 (es) 11*(b)-aryl-17,17-spirothiolane-substituted steroids.
CN108218945B (zh) 去氧胆酸衍生物、其制备方法、药物组合物及用途
CN1607204B (zh) 环磷酰胺季铵盐衍生物及其合成和应用
WO2001044267A1 (de) 11-β-PHENYLESTRADIEN-DERIVATE MIT FLUORALKYLGRUPPEN IN DER AROMATISCHEN SEITENKETTE, DEREN HERSTELLUNG UND DIESE VERBINDUNGEN ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN
WO2025044860A1 (zh) 神经激肽-1受体拮抗剂化合物
CN121449646A (zh) Stat6靶向蛋白降解剂及其制备方法和应用
WO2020056046A1 (en) Near-infrared nerve-sparing benzo[c]phenoxazine fluorophores